Аннотация:The work is done in a series of studies on the development of α-emitter pharmaceutical
"Astatine-211". One of the key objectives of the study is the assessment of radiation exposure to
the eye and lens of the eye in relation to the known cases of eye disease in clinical use of the isotope
131I (which is analog to the developed pharmaceutical "Astatine-211") for the thyroid gland
treatment. To solve this problem in the environment of GEANT-4 was simulated human anatomy
and were evaluated absorbed fractions in the target “eye” from all the organs sources, and the reverse
(“eye” as the source organ) for γ-radiation of standard range energies and α-spectrum of 211At
with a known activity distribution of the pharmaceutical. Modeling the anatomy is based on the
application of standard MIRD phantom model. To go to more accurate estimates of the absorbed
dose within the created software ORNL phantom is introduced, which is specific for age and gender.
Primary testing of ORNL model for γ-radiation was carried out. The created software allows
visualization of particle tracks and anatomy design to prevent inadvertent errors in the initial
conditions of the activity distribution of radiopharmaceuticals. As a result of a study two new organs
the eye and eye-lens are added in the standard adult-human phantom. Software calculations show
that the use of α-emitter radiopharmaceutical "Astatine-211" reduces the radiation exposure on the
eyes and eye-lens by few orders of magnitude in comparison with the use of I-131 with the same
therapeutic doses in the irradiated organ - the thyroid gland